Clinical Trial Evaluate the Cough-relieving and Expectorant Effects of the Health Supplement AZKA Nasal and Throat for Children in Outpatient-treated Pharyngitis

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 23, 2024

Primary Completion Date

February 27, 2025

Study Completion Date

April 28, 2025

Conditions
Cough SeverityCough FrequencyCough DurationPhlegm Accumulation (Nasal and Throat Mucus)
Interventions
DIETARY_SUPPLEMENT

Azka Nasal and Throat for Children

Azka Nasal and Throat for Children is provided as a liquid oral preparation, designed with a pleasant flavor to ensure compliance in pediatric patients. The intervention involves administering 7.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days. The supplement is intended to alleviate symptoms of nasal and throat irritation, reduce phlegm, and improve overall respiratory comfort. Azka Nasal and Throat for Children has been widely used in clinical and community settings, with a favorable safety profile and reported effectiveness in pediatric respiratory care.

DRUG

Prospan cough Syrup

The active comparator, Prospan Cough Syrup is a plant-based herbal medicinal product containing the active ingredient Hedera helix (ivy leaf extract), standardized to ensure consistent pharmacological efficacy. The syrup is formulated as an oral liquid preparation with a pleasant taste suitable for pediatric and adult use. The intervention involves administering 2.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days.

Trial Locations (1)

180000

Center for Clinical Trial and Bioequivalence Study, Haiphong

All Listed Sponsors
lead

Haiphong University of Medicine and Pharmacy

OTHER

NCT06761339 - Clinical Trial Evaluate the Cough-relieving and Expectorant Effects of the Health Supplement AZKA Nasal and Throat for Children in Outpatient-treated Pharyngitis | Biotech Hunter | Biotech Hunter